Drug intelligence / Profile preview

SEN36 + ricin A chain

Development stage
Preclinical
Modality
Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

SEN36 + ricin A chain is an immunotoxin consisting of the monoclonal antibody SEN36 chemically conjugated to the ricin A chain protein. This immunotoxin is designed to selectively target and bind the neural cell adhesion molecule (N-CAM, also known as CD56) on cell surfaces through SEN36, delivering the ricin A chain directly to N-CAM expressing cells. The ricin A chain is a ribosome-inactivating protein (RIP) that enzymatically depurinates a conserved adenosine residue in the 28S rRNA of eukaryotic ribosomes, thereby irreversibly inhibiting protein synthesis and inducing cell death. This construct has been investigated for selective cytotoxicity against N-CAM expressing cancer cells, but evidence indicates that the SEN36-ricin A chain immunotoxin lacked selective cytotoxic activity in tested cell lines[4][1]. Ricin A chain, unlike the complete ricin toxin, lacks the B chain required for broad cell entry, making it dependent on the targeting antibody for cellular delivery and intended specificity[2][1][4]. Primary indications explored for such immunotoxins include N-CAM expressing malignancies.

Other names
SEN36 + ricin A chainSEN36-ricin A chainSEN-36-ricin A chainSEN 36-ricin A chainSEN36-ricin-A-chain immunotoxinSEN-36-ricin-A-chain immunotoxinSEN 36-ricin-A-chain immunotoxin
02

Targets

NCAM1 (Neural cell adhesion molecule 1)SRL (28S rRNA sarcin-ricin loop)

Beyond the preview

Go deeper on SEN36 + ricin A chain.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SEN36 + ricin A chain.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call